References

Ulcerative colitis

10.1016/s0140-6736(23)00966-2 · 2023 · External reference

Natural course of ulcerative colitis in China: differences from the West?

10.1002/ueg2.12634 · 2024 · External reference

Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

10.1186/s12876-022-02225-w · 2022 · External reference

Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: a propensity-matched cohort study

10.1111/apt.17570 · 2023 · External reference

Vedolizumab as induction and maintenance therapy for ulcerative colitis

10.1056/nejmoa1215734 · 2013 · External reference

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

10.1016/s0140-6736(22)00581-5 · 2022 · External reference

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis

10.1016/j.cgh.2026.01.017 · 2026 · External reference

Comparative effectiveness and safety of upadacitinib and vedolizumab in biologic-experienced patients with ulcerative colitis: a retrospective study

10.1111/1751-2980.70012 · 2025 · External reference

Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

10.1016/s2468-1253(21)00377-0 · 2022 · External reference

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

10.1155/2005/269076 · 2005 · External reference

Validation of a combined comorbidity index

10.1016/0895-4356(94)90129-5 · 1994 · External reference

Unresolved reference

External reference

Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: insights from the past two years

10.1097/cm9.0000000000003542 · 2025 · External reference

Real-world comparison of the effectiveness between ustekinumab and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent

10.1093/ecco-jcc/jjae063 · 2024 · External reference

Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent

10.1111/apt.17305 · 2023 · External reference

Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody

10.5217/ir.2024.00148 · 2025 · External reference

Efficacy of upadacitinib induction treatment in moderate-to-severe ulcerative colitis including intestinal ultrasound assessment: a multicenter, real-world observational study

10.3390/jcm14051695 · 2025 · External reference

Upadacitinib’s effectiveness and safety as a second- or third-line therapy in patients with ulcerative colitis: data from a real-world study

10.3390/jcm14217801 · 2025 · External reference

A comparison of the efficacy and safety of ustekinumab and upadacitinib in biologically experienced ulcerative colitis patients

10.3390/biomedicines13102455 · 2025 · External reference

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

10.5217/ir.2024.00127 · 2025 · External reference

Comparative efficacy of biologics and small molecule therapies in improving patient-reported outcomes in ulcerative colitis: systematic review and network meta-analysis

10.1093/ibd/izae163 · 2025 · External reference

Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysis

10.57264/cer-2024-0225 · 2025 · External reference

Comparative efficacy and safety of upadacitinib vs. vedolizumab, ustekinumab, and tofacitinib after induction and maintenance for ulcerative colitis: three matching-adjusted indirect comparisons

10.1007/s12325-024-02912-y · 2024 · External reference

Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis

10.1056/nejmoa1905725 · 2019 · External reference

AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis

10.1053/j.gastro.2024.10.001 · 2024 · External reference